Lana Yin Hui Lai

Lana Yin Hui Lai

Auto-generated profile, based on publicly available information

Lana Yin Hui Lai

The University of Manchester, Division of Informatics, Imaging and Data Sciences, Manchester, United Kingdom

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LLLana Yh Lai
Lana Yh Lai
FAFaaizah Arshad
Faaizah Arshad
CACarlos Areia
Carlos Areia
TAThamir M. Alshammari
Thamir M. Alshammari
HAHeba Alghoul
Heba Alghoul
MSMartijn J. Schuemie
Martijn J. Schuemie
Post-marketing vaccine safety surveillance aims to detect adverse events following immunization in a population. Whether certain methods of surveillance are more precise and unbiased in generating safety signals is unclear. Here, we synthesized information from existing literature to provide an overview of the strengths, weaknesses, and clinical applications of epidemiologic and analytical methods used in vaccine monitoring, focusing on cohort, case-control and self-controlled designs. These designs are proposed to be evaluated in the EUMAEUS (Evaluating Use of Methods for Adverse Event Under Surveillance–for vaccines) study because of their widespread use and potential utility. Over the past decades, there have been an increasing number of epidemiological study designs used for vaccine safety surveillance. While traditional cohort and case-control study designs remain widely used, newer, novel designs such as the self-controlled case series and self-controlled risk intervals have been developed. Each study design comes with its strengths and limitations, and the most appropriate study design will depend on availability of resources, access to records, number and distribution of cases, and availability of population coverage data. Several assumptions have to be made while using the various study designs, and while the goal is to mitigate any biases, violations of these assumptions are often still present to varying degrees. In our review, we discussed some of the potential biases (i.e., selection bias, misclassification bias and confounding bias), and ways to mitigate them. While the types of epidemiological study designs are well established, a comprehensive comparison of the analytical aspects (including method evaluation and performance metrics) of these study designs are relatively less well studied. We summarized the literature, reporting on two simulation studies, which compared the detection time, empirical power, error rate and risk estimate bias across the above-mentioned study designs. While these simulation studies provided insights on the analytic performance of each of the study designs, its applicability to real-world data remains unclear. To bridge that gap, we provided the rationale of the EUMAEUS study, with a brief description of the study design; and how the use of real-world multi-database networks can provide insights into better methods evaluation and vaccine safety surveillance.

17 October 2025 in Journal of Global Health
Verified
Journal Article
Open access
SLSiyi Luo
Siyi Luo
LLLana Yh Lai
Lana Yh Lai
RZRui Zhu
Rui Zhu
YGYudong Gao
Yudong Gao
ZZZhenxi Zhao
Zhenxi Zhao
The outbreak of the COVID-19 pandemic led to approximately two million deaths in 2020 [1]. By January 2024, there were 774 million diagnoses and 6.96 million deaths reported worldwide [2]. COVID-19 is a multi-systemic, multi-organ disease, with multiple clinical manifestations [3]. While it mainly impacts the respiratory system in the acute phase, the disease also […]

16 July 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
ERElena Roel
Elena Roel
APAndrea Pistillo
Andrea Pistillo
MRMartina Recalde
Martina Recalde
ASAnthony G. Sena
Anthony G. Sena
SFSergio Fernández-Bertolín
Sergio Fernández-Bertolín
TDTalita Duarte-Salles
Talita Duarte-Salles
Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.

15 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
JBJuan Banda
Juan Banda
NANicola Adderley
Nicola Adderley
WAWaheed-Ul-Rahman Ahmed
Waheed-Ul-Rahman Ahmed
HAHeba AlGhoul
Heba AlGhoul
OAOsaid Alser
Osaid Alser
DPDaniel Prieto-Alhambra
Daniel Prieto-Alhambra
As the SARS-CoV-2 virus (COVID-19) continues to affect people across the globe, there is limited understanding of the long term implications for infected patients 1–3 . While some of these patients have documented follow-ups on clinical records, or participate in longitudinal surveys, these datasets are usually designed by clinicians, and not granular enough to understand the natural history or patient experiences of ‘long COVID’. In order to get a complete picture, there is a need to use patient generated data to track the long-term impact of COVID-19 on recovered patients in real time. There is a growing need to meticulously characterize these patients’ experiences, from infection to months post-infection, and with highly granular patient generated data rather than clinician narratives. In this work, we present a longitudinal characterization of post-COVID-19 symptoms using social media data from Twitter. Using a combination of machine learning, natural language processing techniques, and clinician reviews, we mined 296,154 tweets to characterize the post-acute infection course of the disease, creating detailed timelines of symptoms and conditions, and analyzing their symptomatology during a period of over 150 days.

5 February 2015 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
LLLana Y. H. Lai
Lana Y. H. Lai
APAndrew B. Petrone
Andrew B. Petrone
JPJames S. Pankow
James S. Pankow
DADonna K. Arnett
Donna K. Arnett
KNKari E. North
Kari E. North
LDLuc Djoussé
Luc Djoussé

27 November 2020 in medRxiv
Verified
Preprint
Open access
PDF file
EBEdward Burn
Edward Burn
ASAnthony G. Sena
Anthony G. Sena
AUAlbert Prats Uribe
Albert Prats Uribe
MSMatthew Spotnitz
Matthew Spotnitz
SDScott DuVall
Scott DuVall
TDTalita Duarte-Salles
Talita Duarte-Salles
Objective: To estimate the proportion of patients hospitalized with COVID-19 who undergo dialysis, tracheostomy, and extracorporeal membrane oxygenation (ECMO). Design: A network cohort study. Setting: Seven databases from the United States containing routinely-collected patient data: HealthVerity, Premier, IQVIA Hospital CDM, IQVIA Open Claims, Optum EHR, Optum SES, and VA-OMOP. Patients: Patients hospitalized with a clinical diagnosis or a positive test result for COVID-19. Interventions: Dialysis, tracheostomy, and ECMO. Measurements and Main Results: 842,928 patients hospitalized with COVID-19 were included (22,887 from HealthVerity, 77,853 from IQVIA Hospital CDM, 533,997 from IQVIA Open Claims, 36,717 from Optum EHR, 4,336 from OPTUM SES, 156,187 from Premier, and 10,951 from VA-OMOP). Across the six databases, 35,192 (4.17% [95% CI: 4.13% to 4.22%]) patients received dialysis, 6,950 (0.82% [0.81% to 0.84%]) had a tracheostomy, and 1,568 (0.19% [95% CI: 0.18% to 0.20%]) patients underwent ECMO over the 30 days following hospitalization. Use of ECMO was more common among patients who were younger, male, and with fewer comorbidities. Tracheostomy was broadly used for a similar proportion of patients regardless of age, sex, or comorbidity. While dialysis was generally used for a similar proportion among younger and older patients, it was more frequent among male patients and among those with chronic kidney disease. Conclusion: Use of dialysis among those hospitalized with COVID-19 is high at around 4%. Although less than one percent of patients undergo tracheostomy and ECMO, the absolute numbers of patients who have undergone these interventions is substantial.